References
- Baillie LW. Is new always better than old?: The development of human vaccines for anthrax. Hum. Vaccin. 5(12), 806–816 (2009).
- Ermini L, Wilson IJ, Goodship TH, Sheerin NS. Complement polymorphisms: geographical distribution and relevance to disease. Immunobiology 217(2), 265–271 (2012).
- Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2(12), 967–977 (2001).
- Ingram RJ, Chu KK, Metan G et al. An epitope of Bacillus anthracis protective antigen that is cryptic in rabbits may be immunodominant in humans. Infect. Immun. 78(5), 2353; author reply 2353–2353; 4 (2010).
- Marano N, Plikaytis BD, Martin SW et al.; Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300(13), 1532–1543 (2008).
- Crowe SR, Garman L, Engler RJ et al. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine 29(20), 3670–3678 (2011).
- Gelder CM, Lambkin R, Hart KW et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185(1), 114–117 (2002).
- Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5(4), 417–427 (2004).
- Davenport MP, Hill AV. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol. Med. Today 2(1), 38–45 (1996).
- Ingram RJ, Metan G, Maillere B et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J. Immunol. 184(7), 3814–3821 (2010).
- Baillie LW, Huwar TB, Moore S et al. An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28(41), 6740–6748 (2010).
- De Groot AS, Martin W. From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Found. Symp. 254, 57–72; discussion 72 (2003).
- Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11(16), 5900–5911 (2005).
- Tang YW, Li H, Wu H, Shyr Y, Edwards KM. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine J. Infect. Dis. 196(7), 1021–1025 (2007).
- Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum. Genet. 130(4), 547–561 (2011).
- Barber GN. Cytoplasmic DNA innate immune pathways. Immunol. Rev. 243(1), 99–108 (2011).
- Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 22(21–22), 2881–2886 (2004).
- Martchenko M, Candille SI, Tang H, Cohen SN. Human genetic variation altering anthrax toxin sensitivity. Proc. Natl Acad. Sci. USA 109(8), 2972–2977 (2012).
- Rosovitz MJ, Schuck P, Varughese M et al. Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278(33), 30936–30944 (2003).
- Pomerantsev AP, Staritsin NA, Mockov YuVMarinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15(17–18), 1846–1850 (1997).